3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
26
Observational
4
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
nilotinib
5
venetoclax
3
midostaurin
3
ponatinib
2
navitoclax
2
gilteritinib
2
fludarabine phosphate
2
asparaginase erwinia chrysanthemi recombinant
2
tisagenlecleucel
1
revumenib
1
pirtobrutinib
1
magrolimab
1
ivosidenib
1
immunotoxin HA22
1
idelalisib
1
ibrutinib
1
glucarpidase
1
fludarabine
1
eryaspase
1
enasidenib
1
cc-486
1
brexucabtagene autoleucel
1
asciminib
1
Whole-Body Irradiation
1
Transplantation
1
Tacrolimus
1
Rituximab
1
Mycophenolic Acid
1
Immunotherapy, Adoptive
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
asciminib
×
Other hematologic neoplasm
×
Clear all
NCT04360005
2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available